References
1. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P.
Incidence of cancer in 98 patients with common varied immunodeficiency.
J Clin Immunol. 1987 Jul;7(4):294–9.
2. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary
immunodeficiency diseases associated with increased susceptibility to
viral infections and malignancies. J Allergy Clin Immunol. 2011
Jun;127(6):1329-1341.e2; quiz 1342–3.
3. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello
D. Common variable immunodeficiency: crossroads between infections,
inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796–801.
4. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton
S. Are antibody deficiency disorders associated with a narrower range of
cancers than other forms of immunodeficiency? Blood. 2010 Aug
26;116(8):1228–34.
5. Shapiro RS. Malignancies in the setting of primary immunodeficiency:
Implications for hematologists/oncologists. Am J Hematol. 2011
Jan;86(1):48–55.
6. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK.
Immunodeficiency-associated lymphomas. Blood Rev. 2008
Sep;22(5):261–81.
7. Mellemkjaer L, Hammarström L, Andersen V, Yuen J, Heilmann C,
Barington T, et al. Cancer risk among patients with IgA deficiency or
common variable immunodeficiency and their relatives: a combined Danish
and Swedish study. Clin Exp Immunol. 2002;130(3):495–500.
8. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G,
Jaussaud R, et al. Infections in 252 patients with common variable
immunodeficiency. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008 May
15;46(10):1547–54.
9. Cunningham-Rundles C. The many faces of common variable
immunodeficiency. Hematol Am Soc Hematol Educ Program. 2012;2012:301–5.
10. CEREDIH: The French PID study group. The French national registry of
primary immunodeficiency diseases. Clin Immunol Orlando Fla. 2010
May;135(2):264–72.
11. Picard C, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME,
et al. Primary Immunodeficiency Diseases: an Update on the
Classification from the International Union of Immunological Societies
Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015
Nov;35(8):696–726.
12. Chan H-Y, Yang Y-H, Yu H-H, Chien Y-H, Chiang L-L, Chiang B-L.
Clinical characteristics and outcomes of primary antibody deficiency: a
20-year follow-up study. J Formos Med Assoc Taiwan Yi Zhi. 2014
Jun;113(6):340–8.
13. Dabaja BS, Advani R, Hodgson DC, Dhakal S, Flowers CR, Ha CS, et al.
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma: Am J Clin
Oncol. 2015 Dec;38(6):610–20.
14. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani
RH, et al. NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version
3.2016. J Natl Compr Cancer Netw JNCCN. 2016;14(9):1067–79.
15. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M,
Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 2015 Sep;26:v116–25.
16. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L,
Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia
and multiple myeloma: systematic review and meta-analysis. Leuk
Lymphoma. 2009 May;50(5):764–72.
17. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin
replacement therapy (IGRT) in antibody deficiency: a practical approach:
When to initiate IgG therapy in antibody deficiency. Clin Exp Immunol.
2017 Jun;188(3):333–41.
18. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary
Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol
[Internet]. 2019 Feb 8 [cited 2020 Aug 24];10. Available from:
https://www.frontiersin.org/article/10.3389/fimmu.2019.00033/full
19. Benbrahim O, Viallard J-F, Choquet S, Royer B, Bauduer F, Decaux O,
et al. A French observational study describing the use of human
polyvalent immunoglobulins in hematological malignancy-associated
secondary immunodeficiency. Eur J Haematol. 2018 Jul;101(1):48–56.
20. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans
J, et al. The European Society for Immunodeficiencies (ESID) Registry
Working Definitions for the Clinical Diagnosis of Inborn Errors of
Immunity. J Allergy Clin Immunol Pract. 2019 Aug;7(6):1763–70.
21. Ameratunga R, Woon S-T, Gillis D, Koopmans W, Steele R. New
diagnostic criteria for common variable immune deficiency (CVID), which
may assist with decisions to treat with intravenous or subcutaneous
immunoglobulin. Clin Exp Immunol. 2013 Nov;174(2):203–11.
22. Ameratunga R, Woon S-T. Perspective: Evolving Concepts in the
Diagnosis and Understanding of Common Variable Immunodeficiency
Disorders (CVID). Clin Rev Allergy Immunol. 2020 Aug;59(1):109–21.
23. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK,
Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of
4539 cases from the International Non-Hodgkin Lymphoma Classification
Project. Haematologica. 2016 Oct;101(10):1244–50.
24. Desandes E, Lacour B, Clavel J, le Réseau français des registres de
cancers. [Cancer in adolescents and young adults in France:
Epidemiology and pathways of care]. Bull Cancer (Paris). 2016
Dec;103(12):957–65.
25. Mahlaoui N, Picard C, Bach P, Costes L, Courteille V,
Ranohavimparany A, et al. Genetic diagnosis of primary
immunodeficiencies: A survey of the French national registry. J Allergy
Clin Immunol. 2019 Apr;143(4):1646-1649.e10.